EP Patent

EP1863839B1 — Acylated glp-1 compounds

Assigned to Novo Nordisk AS · Expires 2010-08-04 · 16y expired

What this patent protects

Protracted GLP-1 compounds and therapeutic uses thereof.

USPTO Abstract

Protracted GLP-1 compounds and therapeutic uses thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP1863839B1
Jurisdiction
EP
Classification
—
Expires
2010-08-04
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.